Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

This roundup highlights recent FDA updates related to drug approvals and devices used by optometric eye care professionals.

FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.

Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

Retinal vein occlusion (RVO) is a severe disease that occurs when a vein in the light-sensitive layer at the back of the eye ...

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, ...

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...

INCHEON, Korea, January 02, 2026--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), ...

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the ...